These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20376669)

  • 1. Pathophysiology and antioxidant status of patients with fibromyalgia.
    Iqbal R; Mughal MS; Arshad N; Arshad M
    Rheumatol Int; 2011 Feb; 31(2):149-52. PubMed ID: 20376669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome.
    Crofford LJ
    Z Rheumatol; 1998; 57 Suppl 2():67-71. PubMed ID: 10025087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome.
    Tanriverdi F; Karaca Z; Unluhizarci K; Kelestimur F
    Stress; 2007 Mar; 10(1):13-25. PubMed ID: 17454963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.
    Ozgocmen S; Ozyurt H; Sogut S; Akyol O
    Rheumatol Int; 2006 May; 26(7):585-97. PubMed ID: 16328420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome.
    Demitrack MA; Crofford LJ
    Ann N Y Acad Sci; 1998 May; 840():684-97. PubMed ID: 9629295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia.
    McLean SA; Williams DA; Stein PK; Harris RE; Lyden AK; Whalen G; Park KM; Liberzon I; Sen A; Gracely RH; Baraniuk JN; Clauw DJ
    Neuropsychopharmacology; 2006 Dec; 31(12):2776-82. PubMed ID: 16936702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis.
    Scott LV; Dinan TG
    Funct Neurol; 1999; 14(1):3-11. PubMed ID: 10321324
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome.
    Neeck G; Crofford LJ
    Rheum Dis Clin North Am; 2000 Nov; 26(4):989-1002. PubMed ID: 11084955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals.
    Glass JM; Lyden AK; Petzke F; Stein P; Whalen G; Ambrose K; Chrousos G; Clauw DJ
    J Psychosom Res; 2004 Oct; 57(4):391-8. PubMed ID: 15518675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premorbid "overactive" lifestyle and stress-related pain/fatigue syndromes.
    Van Houdenhove B
    J Psychosom Res; 2005 Apr; 58(4):389-90. PubMed ID: 15992575
    [No Abstract]   [Full Text] [Related]  

  • 11. Psychiatric aspects of chronic fatigue syndrome and fibromyalgia.
    Van Houdenhove B; Kempke S; Luyten P
    Curr Psychiatry Rep; 2010 Jun; 12(3):208-14. PubMed ID: 20425282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome.
    Bradley LA; McKendree-Smith NL; Alarcón GS
    Curr Rev Pain; 2000; 4(2):148-57. PubMed ID: 10998728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine mechanisms in fibromyalgia-chronic fatigue.
    Buskila D; Press J
    Best Pract Res Clin Rheumatol; 2001 Dec; 15(5):747-58. PubMed ID: 11812019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome.
    Calis M; Gökçe C; Ates F; Ulker S; Izgi HB; Demir H; Kirnap M; Sofuoglu S; Durak AC; Tutus A; Kelestimur F
    J Endocrinol Invest; 2004 Jan; 27(1):42-6. PubMed ID: 15053242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine changes and maladaptations in fibromyalgia. Etiopathogenetic findings].
    Thieme K
    Orthopade; 2004 May; 33(5):576-82. PubMed ID: 15138685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
    Crofford LJ; Pillemer SR; Kalogeras KT; Cash JM; Michelson D; Kling MA; Sternberg EM; Gold PW; Chrousos GP; Wilder RL
    Arthritis Rheum; 1994 Nov; 37(11):1583-92. PubMed ID: 7980669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats.
    Surapaneni DK; Adapa SR; Preeti K; Teja GR; Veeraragavan M; Krishnamurthy S
    J Ethnopharmacol; 2012 Aug; 143(1):91-9. PubMed ID: 22771318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and antioxidative parameters and metal ion content in patients with fibromyalgia syndrome: implications in the pathogenesis of the disease.
    Fatima G; Das SK; Mahdi AA
    Clin Exp Rheumatol; 2013; 31(6 Suppl 79):S128-33. PubMed ID: 24373371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co-morbidities.
    Singh L; Kaur A; Bhatti MS; Bhatti R
    Neurochem Res; 2019 Jul; 44(7):1517-1532. PubMed ID: 31004261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine immunology of fibromyalgia.
    Di Franco M; Iannuccelli C; Valesini G
    Ann N Y Acad Sci; 2010 Apr; 1193():84-90. PubMed ID: 20398012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.